Zia Farah Z, Olaku Oluwadamilola, Bao Ting, Berger Ann, Deng Gary, Fan Arthur Yin, Garcia Mary K, Herman Patricia M, Kaptchuk Ted J, Ladas Elena J, Langevin Helene M, Lao Lixing, Lu Weidong, Napadow Vitaly, Niemtzow Richard C, Vickers Andrew J, Shelley Wang Xin, Witt Claudia M, Mao Jun J
Division of Cancer Treatment and Diagnosis, Office of Cancer Complementary and Alternative Medicine, National Cancer Institute, National Institutes of Health, Rockville, MD; Kelly Services, Incorporated, Rockville, MD, and Division of Cancer Treatment and Diagnosis, Office of Cancer Complementary and Alternative Medicine, National Cancer Institute, National Institutes of Health, Rockville, MD; Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Pain and Palliative Care Service, National Institutes of Health Clinical Center, Rockville, MD; McLean Center for Complementary and Alternative Medicine, PLC, Vienna, VA; Department of General Oncology/Integrative Medicine Program, MD Anderson Cancer Center, Houston, TX; Health Division, RAND Corporation, Santa Monica, CA; Program in Placebo Studies, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA; Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Columbia University, New York, NY; Osher Center for Integrative Medicine, Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; School of Chinese Medicine, University of Hong Kong, Hong Kong, China; Leonard P. Zakim Center for Integrative Therapies, Dana-Farber Cancer Institute, Boston, MA; Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston MA; United States Air Force Acupuncture and Integrative Medical Center, Joint Base Andrews, MD; Department of Symptom Research, MD Anderson Cancer Center, Houston, TX; Institute for Complementary and Integrative Medicine, University of Zurich and University Hospital Zurich, Zurich, Switzerland; Institute for Social Medicine, Epidemiology and Health Economics, Charité, Universitätsmedizin Berlin, Germany; Center for Integrative Medicine, University of Maryland School of Medicine, Baltimore, MD.
J Natl Cancer Inst Monogr. 2017 Nov 1;2017(52). doi: 10.1093/jncimonographs/lgx005.
The Division of Cancer Treatment and Diagnosis, Office of Cancer Complementary and Alternative Medicine, at the National Cancer Institute (NCI) held a symposium on "Acupuncture for Cancer Symptom Management" on June 16 and 17, 2016. Invited speakers included 19 scientists and scholars with expertise in acupuncture and cancer research from the United States, Europe, and China. The conference reviewed the NCI's grant funding on acupuncture, analyzed the needs of cancer patients, reviewed safety issues, and assessed both the current scientific evidence and research gaps of acupuncture in oncology care. Researchers and stakeholders presented and discussed basic mechanisms of acupuncture; clinical evidence for specific symptoms; and methodological challenges such as placebo effects, novel biostatistical methods, patient-reported outcomes, and comparative effectiveness research. This paper, resulting from the conference, summarizes both the current state of the science and clinical evidence of oncology acupuncture, identifies key scientific gaps, and makes recommendations for future research to increase understanding of both the mechanisms and effects of acupuncture for cancer symptom management.
2016年6月16日至17日,美国国立癌症研究所(NCI)癌症补充与替代医学办公室癌症治疗与诊断司举办了一场关于“针灸用于癌症症状管理”的研讨会。受邀发言者包括来自美国、欧洲和中国的19位在针灸与癌症研究方面具有专业知识的科学家和学者。会议回顾了NCI对针灸的资助情况,分析了癌症患者的需求,审查了安全问题,并评估了针灸在肿瘤护理方面的现有科学证据和研究空白。研究人员和利益相关者介绍并讨论了针灸的基本机制;特定症状的临床证据;以及诸如安慰剂效应、新型生物统计学方法、患者报告结果和比较效果研究等方法学挑战。本文源自此次会议,总结了肿瘤针灸的科学现状和临床证据,确定了关键的科学空白,并为未来研究提出建议,以增进对针灸治疗癌症症状的机制和效果的理解。